The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS.

ProMIS Neurosciences is working to detect, target and treat the root causes of neurodegenerative diseases affecting millions of families globally


Key reasons to consider an investment in ProMIS Neurosciences
  1. Massive market opportunity and unmet medical need in Alzheimer’s disease. No therapies available today to stop the progression of Alzheimer’s disease (AD). Total US AD healthcare costs > $500BB, expected to triple over next 10-15 years. ProMIS product candidates are uniquely designed to selectively block the toxic strains of Amyloid beta, to stop the fundamental, underlying driver causing death of brain neurons in AD.

  2. Management team. Experienced, complementary management team with outstanding scientific and business advisory boards.

  3. Significant risk mitigation/reduction of ProMIS proposed product candidates. Big pharma has spent $BB on failed, or partially successful clinical trials in AD. Results of these trials clearly indicate the ideal target product profile to develop, i.e., to succeed, products must target the toxic prion forms of Amyloid beta, and not target the other forms of Amyloid beta. ProMIS products are designed to selectively target these toxic strains of Amyloid beta, supporting a highly differentiated, best in class product profile.

  4. ProMIS proprietary discovery engine supports development of a broad product portfolio in neurodegenerative diseases. Use of the ProMIS discovery platform allows to identify novel therapeutic targets on various toxic, misfolded proteins responsible for multiple neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS, and other dementias such as Lewy Body dementia, frontotemporal dementia, and chronic head trauma

Harnessing the Power of Precision Medicine




Massive market opportunity & unmet medical need

No therapies available today to stop progression of Alzheimer’s disease (AD). Total US AD healthcare costs > $500BB, expected to triple over next 10-15 years. ProMIS products are uniquely designed to block the toxic strains of Amyloid beta, to stop the fundamental, underlying driver causing death of brain neurons in AD.

Management team

Experienced, complementary management team with outstanding scientific and business advisory boards.

Significant risk mitigation/reduction of ProMIS proposed products

Big pharma spent $BB on failed, or partially successful clinical trials. Results of these trials clearly indicate the ideal target product profile, i.e., to succeed, products must target the toxic prion form of Amyloid beta, and not target the other forms of Amyloid beta.

ProMIS products are designed to target uniquely these toxic strains of Amyloid beta.


  • Exchange & Symbol:                   TSX: PMN
  • Issued and Outstanding:         170,363,473
  • Fully Diluted:                                  201,469,914
  • Auditor:                                             PricewaterhouseCoopers LLP
  • Legal Firm:                                       Bereskin & Parr

Website:        ProMis Neuroscience
Stock Info:


  • All information provided is “as is” for informational and educational purposes only, and not intended for trading or investment advice. 8020 does not advocate the purchase or sale of a security or investment mentioned and recommends any investment advice should be obtained through professional and licensed investment advisors.
  • 8020 Connect does not screen, audit, evaluate, endorse, recommend or represent a product, service, or the individual companies listed or posted on the 8020 site. Should you decide to purchase any product or service, advocate or invest in a company listed on 8020, you do so at your own risk.
  • The information displayed on the 8020 site should not be construed as an offer to buy, sell, solicit or influence an investment decision by 8020 or its employees, officers, directors or consultants. Any investment or security referred to or learned about on the 8020 site are not suitable for all investors, and investment advice from a licensed investment advisor is highly recommended.
  • It is possible that 8020 and its employees, officers, directors or consultants may have investments in a company listed on the 8020 site.
  • 8020 Connect provides the technology platform for 8020 connect members on an “as is” and “as available” basis. 8020 Connect does not provide any express warranties or representations to the full extent permissible under the applicable law.
  • 8020 Connect does not have an obligation to monitor user activity and therefore disclaims all liability for identity theft or other misuse of your identity or information.
  • 8020 Connect does not guarantee that its services will function without interruption or errors during its service whether from external factors, internal maintenance, user issues, or any other reason. 8020 Connect disclaims all liability for damages or loss of income due to the above interruptions, errors or issues.
Eugene Williams is a former SVP at Genzyme, with senior roles integrating commercialization, drug development, and deal making. He is also an entrepreneur, as the founder and director of Adheris, which became the largest company in the patient adherence area. He was previously a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was co-Head of Healthcare and spent extensive time on speeding and improving the drug development process and on commercialization strategies. Mr. Williams was most recently the CEO of Dart Therapeutics, an Orphan Disease drug development company. Mr. Williams holds a B.A. from Harvard University and an M.B.A. from Harvard Business School.
Elliot Goldstein brings a unique track record in the clinical, regulatory and commercial development of new pharmaceuticals. Dr. Goldstein began his career with Sandoz Pharmaceuticals (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters, including as Head of Clinical R&D in the United States. He subsequently held positions as SVP of Strategic Product Development at SmithKline Beecham (now GSK), CEO of British Biotech (Oxford, UK), Chief Operating Officer and Chief Medical Officer of Maxygen, and President and CMO of a startup biotech devoted to development of biosimilar monoclonal antibodies. Dr. Goldstein holds an M.D. from the University Aix-Marseille II, Marseille, France, and a B.Sc. from McGill University, Montreal.
Dr. Cashman is a physician and scientist focused on neurodegenerative diseases. His first academic posting was at Montreal Neurological Institute and Hospital of McGill University. From 1998 to 2005, he was the Diener Professor of Neurodegenerative Diseases at the University of Toronto. In 2005, Professor Cashman moved to the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases, and serves as the Director of the UBC ALS Centre. He has procured over $50 million in research grant funding from the CIHR, CRC, NCE, NIH, and various corporations for his work involving protein misfolding and prion technologies. He was awarded the Jonas Salk Prize for biomedical research in 2000, and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
Prof. Steven Plotkin is a theoretical and computational biophysicist whose research focuses on protein folding and misfolding in neurodegenerative disease, protein evolution and cellular differentiation, and the molecular mechanisms of cancer. He has been a professor at UBC in the Department of Physics and Astronomy since 2001, where he was appointed as the Canada Research Chair in Theoretical Molecular Biophysics. He was an Alfred P. Sloan Research Fellow in 2005-2006, a Killam Faculty Research Fellow in 2010, and is now an associate member of the Genome Sciences and Technology Program, the Bioinformatics Program, and the Institute for Applied Mathematics at the University of British Columbia. Several of his publications have received the Faculty of 1000 designation, placing them in the top 2% of published articles in biology and medicine.
Plotkin is recognized internationally for his fundamental contributions to the energy landscape theory of protein folding, and presents his research findings in protein misfolding and neurodegeneration, and protein geometry and disorder as an invited speaker at several annual conferences and symposia. His research is currently supported by grants from CIHR, NSERC, APRI, ALS-Canada, and Compute Canada.
Senior partner at Kirwin LLP, has been advising and representing businesses in a range of industries and sizes from local to multinational for over 30 years. He obtained his B.A. in Economics (First Class Standing) from the University of Alberta in 1978 followed by his J.D. from the University of Toronto, Faculty of law in 1982. He practiced initially with the Canadian Federal Department of Justice from 1982 to 1986 then founded the predecessor to Kirwin LLP where he currently practices in Edmonton Alberta.
William W. Wyman began his career at the management consulting firm Booz Allen and Hamilton. After working for the firm in New York, Duesseldorf Germany, Athens Greece, and Dallas Texas, he returned to New York to become the President of the Management Consulting Group, a member of the executive committee, and a member of the Board of Directors. Subsequently, Mr. Wyman co-founded the management consulting firm, Oliver Wyman & Co. Now part of Marsh & McLennan, the firm employs 3,700 professionals in 26 countries. Mr Wyman has served as director to more than eighteen public and private companies, mostly smaller companies in the technology and finance sectors. He also has served as an advisor to several private equity partnerships. Mr. Wyman received his BA from Colgate University, and his MBA from the Harvard Business School. He also served in the U.S. Navy for four years. He resides in Hanover, NH.
Mr. Roth is the founding director and partner at FiveT Capital Holding AG, a Swiss-based innovative financial holdings firm with activities in quantitative tailored investment and risk management solutions for institutional investors and high net-worth individuals with sophisticated wealth management, investment and risk requirements. He has many years of experience as a CIO and portfolio manager for FiveT Capital AG and as an equity specialist and proprietary trader at Baaderbank AG.

Mr. Roth holds a masters degree in economics from Hohenheim University and is a board member of Insilico Biotechnology AG, a Stuttgart/Germany-based global leader in providing solutions and software for the simulation of living cells
Johanne Kaplan is a former VP of Research at Genzyme, a Sanofi Company. Over the course of her 24-year career at Genzyme, Dr. Kaplan directed pioneering research leading to the implementation of multiple clinical trials in the fields of gene therapy, cancer immunotherapy and autoimmunity. Most recently, as VP of Neuroimmunology Research, Dr. Kaplan led the contribution of the Genzyme science team supporting the approval of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. She also established partnerships for the development of novel therapies for neuroinflammatory disorders. Prior to joining Genzyme, Dr. Kaplan was an Associate Immunopathologist at SmithKline Beecham where she established an Immunotoxicology program. Her work has resulted in over 60 scientific publications and multiple patents. Dr. Kaplan holds a Ph.D. in Microbiology & Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York, USA.
Daniel Geffken is a Founding Managing Director of Danforth Advisors, LLC, a consulting firm providing finance, operations and strategic support to life science companies. He brings more than 25 years of experience in the life science industry to his work with ProMIS, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He previously served as COO or CFO of four publicly traded and four privately held life science companies, in addition to his consulting clients. Daniel has been chief financial officer of Homology, Inc, GenePeeks, Inc., Transkaryotic Therapies, Inc., Cidara, Inc., Apellis, Inc. and Stealth BioTherapeutics, Inc. He has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a B.S. from The Wharton School, University of Pennsylvania, and M.B.A. from Harvard Business School.
Anthony J. Giovinazzo has over of thirty-eight years of professional experience, including seven years as an international corporate tax specialist and eight years in investment banking and private equity. For the last 23 years he has solely focussed on the discovery, development and commercialization of neurodegenerative disease therapeutics. Since October 2016 he has been the President and CEO of Sunovion CNS Development Canada ULC., a successor company to Cynapsus Therapeutics Inc., which was purchased by Sunovion Pharmaceuticals, a member of the Dainipon Sumitomo Pharma group of Japan. He was President, CEO and a Director of Cynapsus Therapeutics from 2009 to 2016 and one of the three original inventors and patent holders of the company’s Parkinson’s focussed technology, leading the successful development of APL 130277 (a sublingual strip of apomorphine) through to late stage Phase 3 studies. In addition, he led the company’s up-listing from the TSX Venture exchange to the TSX and then the NASDAQ, attracting bulge bracket investment banks and some of the largest institutional life science investors in the USA. Anthony is the co-author of several peer reviewed papers and author of several papers on strategic and financing issues in the biopharmaceutical industry. He is a Chartered Director and Audit Committee Certified, both from The Directors College of Mc Master University, Hamilton Canada. Anthony obtained his MBA from IMD, Geneva Switzerland ; a Graduate Certificate Studies in Canadian Law from Osgoode Hall Law School, York University, Toronto; and his BA in Economics and Accounting from McMaster University.
Richard Gregory joined ImmunoGen as Chief Scientific Officer & Executive VP for Research in January of 2015. In this capacity he provides leadership and direction to the Research organization and is responsible for the generation of development candidates based upon ImmunoGen’s Antibody Drug Conjugate technology. Prior to ImmunoGen, Richard held a variety of roles at Genzyme and Sanofi-Genzyme, including Vice President for Gene Therapy, Head of Corporate Research and Head of R&D for the Sanofi/Genzyme R&D Center. Rich received his B.Sc. in Biochemistry from Virginia Tech, his Ph.D. in Biochemistry from the University of Massachusetts, and did his post-doctoral training in cancer genetics at the Worcester Foundation for Experimental Biology. He is the co-author of over 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology. Richard is a Fellow of the American Institute for Medical and Biological Engineering.

Industry Articles
Stages of Alzheimer’...
There are three main stages of Alzheimer’s Disease, and while the disease affects each individual in a unique way, the disease can be categorized i...
Read More
Day-to-Day Living wi...
Caring for someone with Alzheimer’s or Dementia can be a rewarding job, whether you’re a hired care-giver or a loved one taking care of another lov...
Read More
Early & Younger-Onse...
Alzheimer’s Disease can be a daunting diagnosis, especially if it comes before it typically should. Younger-onset Alzheimer’s affects those under 6...
Read More
History of Alzheimer's
Today, Alzheimer’s is a leading cause of death and over 560,000 Canadians are living with dementia as of 2016. This number is expected to rise to o...
Read More